A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

To establish the maximum tolerated dose (MTD), dose‐limiting toxicities (DLT), safety profile, and anti‐tumor efficacy of RAF265. We conducted a multicenter, open‐label, phase‐I, dose‐escalation trial of RAF265, an orally available RAF kinase/VEGFR‐2 inhibitor, in patients with advanced or metastati...

詳細記述

保存先:
書誌詳細
出版年:Cancer Med
主要な著者: Izar, Benjamin, Sharfman, William, Hodi, F. Stephen, Lawrence, Donald, Flaherty, Keith T., Amaravadi, Ravi, Kim, Kevin B., Puzanov, Igor, Sosman, Jeffrey, Dummer, Reinhard, Goldinger, Simone M., Lam, Lyhping, Kakar, Shefali, Tang, Zhongwen, Krieter, Oliver, McDermott, David F., Atkins, Michael B.
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2017
主題:
Clinical Cancer Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5548886/
https://ncbi.nlm.nih.gov/pubmed/28719152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1140
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料